Dr. Daver on Updated Findings With Magrolimab/Azacitidine in MDS

Naval G. Daver, MD, an associate professor in the Department of Leukemia within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses updated findings on the combination of the investigational CD47-directed antibody magrolimab (formerly 5F9) and azacitidine in myelodysplastic syndrome.